NDAORALTABLET
Approved
Jan 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Winstrol (stanozolol) is an oral anabolic-androgenic steroid approved in 1962 for treating conditions like angioedema and certain anemias. It works by binding to androgen receptors to promote protein synthesis and red blood cell production. The product is now primarily used off-label in performance enhancement and veterinary applications.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), team focus is shifting toward retention strategies and off-label market defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Winstrol offers limited career growth within a legacy, LOE-approaching franchise with zero linked job openings. Career value lies in managing product decline, defending market share against generics, and ensuring regulatory compliance rather than driving innovation or expansion.
Regulatory Affairs SpecialistCompliance Officer
Worked on WINSTROL at Lundbeck? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.